Affiliation:
1. University of Toronto, 5762 Highway 7 East, Suite 201 Markham, Ontario, L3P 1A8, Canada.
Abstract
Atopic dermatitis (AD) is a common condition affecting an estimated 10–15% of school-aged children. It has a cyclical disease course involving periods of clear skin, early signs/symptoms and flares. Traditionally, pediatric AD was treated mainly with topical corticosteroids; however, nonsteroidal topical calcineurin inhibitors, pimecrolimus 1% cream and tacrolimus 0.03% ointment are welcome additions to the therapeutic arsenal. Pimecrolimus is indicated for mild and moderate AD and tacrolimus for moderate and severe disease. As topical calcineurin inhibitors are increasingly accepted in the AD ‘continuum of care’, a need to distinguish the optimal roles of these agents has emerged. This article reviews clinical and safety data of pimecrolimus 1% cream in pediatric AD compared with vehicle and tacrolimus 0.03% ointment.
Subject
Pediatrics,Pediatrics, Perinatology, and Child Health
Reference53 articles.
1. McCallCO, Lawley TJ: Eczema, psoriasis, cutaneous infections, acne and other common skin disorders. In:Harrison’s Principles of Internal Medicine (16th Edition). Kasper DL, Isselbacher KJ (Eds). McGraw-Hill Medical Publishing Division, Toronto, Canada,288–296 (2005).
2. RajkaG: Clinical aspects. In:Essential Aspects of Atopic Dermatitis. Rajka G (Ed.). Springer-Verlag Berlin, Germany4–55 (1989).
3. Atopic dermatitis: Predictions, expectations, and outcomes